Introduction: Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by vasculopathy and excessive production of collagen, which lead to skin and visceral fibrosis. The aim of our study is to assess the potential benefits of autologous peripheral blood mononuclear cells (PBMCs) implants in the treatment of clinical manifestations such as mouth impairment, hand disability, digital ulcers and Raynaud’s phenomenon in Scleroderma patients. Methods: From February 2016 to May 2019, 10 female patients were enrolled from the outpatient clinic of the Plastic Surgery Unit of Sapienza University of Rome. Parameters evaluated were: patients’ disability, using the Health Assessment Questionnaire (HAQ) disability index (DI) and the scleroderma HAQ (sHAQ); mouth opening capacity, by measuring the maximum interincisal distance and the mouth perimeter; hand mobility, assessed with clinical exam and the Hand Mobility in Scleroderma (HAMIS) scale; Raynaud’s phenomenon, evaluated through nailfold capillaroscopy; digital ulcers, examined through their features and incidence of appearance. SPSS software was used for a simple descriptive statistical analysis performed by the Student’s paired t-test. P values less than 0.05 were considered statistically significant. Results: The treatment showed a significant improvement of all the parameters evaluated at 1-year follow-up, it was well-tolerated by all the patients and the only complications noticed were small areas of ecchymosis. Conclusions: With our preliminary study we tought to exploit PBMCs capability to induce angiogenesis widely described in literature in order to treat the vasculopathy-related manifestations of SSc, in patients with no chance for lipofilling. Our results suggest that PBMCs injection could represent a treatment option to take into account for SSc patients. The procedure we used is easy and fast to perform, minimally invasive and not-operator dependent. We hope our observational and preliminary study could be considered as a starting point for further research studies.

The Use of Peripheral Blood-Mononuclear Cells in Scleroderma Patients: An Observational Preliminary Study / Carella, S; Rossi, C; Ribuffo, D; Onesti, Mg. - In: JOURNAL OF BIOMEDICAL RESEARCH AND REVIEWS. - ISSN 2581-7388. - 4:1(2021), pp. 22-31.

The Use of Peripheral Blood-Mononuclear Cells in Scleroderma Patients: An Observational Preliminary Study

S Carella
Writing – Review & Editing
;
D Ribuffo
Supervision
;
MG Onesti
Visualization
2021

Abstract

Introduction: Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by vasculopathy and excessive production of collagen, which lead to skin and visceral fibrosis. The aim of our study is to assess the potential benefits of autologous peripheral blood mononuclear cells (PBMCs) implants in the treatment of clinical manifestations such as mouth impairment, hand disability, digital ulcers and Raynaud’s phenomenon in Scleroderma patients. Methods: From February 2016 to May 2019, 10 female patients were enrolled from the outpatient clinic of the Plastic Surgery Unit of Sapienza University of Rome. Parameters evaluated were: patients’ disability, using the Health Assessment Questionnaire (HAQ) disability index (DI) and the scleroderma HAQ (sHAQ); mouth opening capacity, by measuring the maximum interincisal distance and the mouth perimeter; hand mobility, assessed with clinical exam and the Hand Mobility in Scleroderma (HAMIS) scale; Raynaud’s phenomenon, evaluated through nailfold capillaroscopy; digital ulcers, examined through their features and incidence of appearance. SPSS software was used for a simple descriptive statistical analysis performed by the Student’s paired t-test. P values less than 0.05 were considered statistically significant. Results: The treatment showed a significant improvement of all the parameters evaluated at 1-year follow-up, it was well-tolerated by all the patients and the only complications noticed were small areas of ecchymosis. Conclusions: With our preliminary study we tought to exploit PBMCs capability to induce angiogenesis widely described in literature in order to treat the vasculopathy-related manifestations of SSc, in patients with no chance for lipofilling. Our results suggest that PBMCs injection could represent a treatment option to take into account for SSc patients. The procedure we used is easy and fast to perform, minimally invasive and not-operator dependent. We hope our observational and preliminary study could be considered as a starting point for further research studies.
2021
peripheral blood mononuclear cells; systemic sclerosys; cell therapy; wound healing
01 Pubblicazione su rivista::01a Articolo in rivista
The Use of Peripheral Blood-Mononuclear Cells in Scleroderma Patients: An Observational Preliminary Study / Carella, S; Rossi, C; Ribuffo, D; Onesti, Mg. - In: JOURNAL OF BIOMEDICAL RESEARCH AND REVIEWS. - ISSN 2581-7388. - 4:1(2021), pp. 22-31.
File allegati a questo prodotto
File Dimensione Formato  
Carella_The-Use-of-Peripheral_2021.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.08 MB
Formato Adobe PDF
1.08 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1681882
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact